Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1405&sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1406&sort=awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1404&sort=awardee_organization" }, "data": [ { "type": "Grant", "id": "15739", "attributes": { "award_id": "1RF1NS144213-01", "title": "SARS-CoV-2 initiation and acceleration of AD pathology in the setting of endogenous and exogenous risk factors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32579, "first_name": "WILLIAM PATRICK", "last_name": "DALEY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-15", "end_date": "2029-07-31", "award_amount": 3039032, "principal_investigator": { "id": 8182, "first_name": "Ananth V", "last_name": "Annapragada", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 7071, "first_name": "Shannon", "last_name": "Ronca", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32793, "first_name": "Andrew Arun", "last_name": "Badachhape", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 32794, "first_name": "Parag", "last_name": "Parekh", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2610, "ror": "", "name": "BAYLOR COLLEGE OF MEDICINE", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The uncertain e,ology of Alzheimer’s disease poses significant obstacles to the development of both therapeu,c and preven,on strategies. At the root of this quandary is the fact that familial disease accounts for a very small frac,on of cases, with the vast majority remaining gene,cally sporadic. The most widely known risk factor, the ApoE4 allele of the gene coding for apolipoprotein E, has been iden,fied, but mechanis,c ,es to disease development are s,ll emerging. Neuroinflamma,on has long been suspected as a contribu,ng factor, and regular exercise documented as a mi,ga,ng factor, with theories to explain their effects being posed, but again with liGle mechanis,c proof. A picture of a very complex process of ini,a,on and progression of Alzheimers disease and related demen,as (AD/RD) including Pick’s disease, fronto-temporal demen,a (FTD) and other tauopathies, is slowly emerging. A key factor in the e,ology of AD/RD that repeatedly crops up is viral infec,on. COVID-19 has brought new aGen,on to this factor, with the observa,on that a frac,on of those infected experience “brain-fog”, a catch-all term that includes cogni,ve dysfunc,on, memory dysfunc,on and mental fa,gue, marked by impaired ability to perform mental tasks compared to before the infec,on. Several factors however, complicate an understanding of the effect of COVID-19 on AD/RD and cons%tute the driving ques%ons for this proposal: These include (1) What are the rela,ve contribu,ons of gene,c risk factors and COVID-19 on ini,a,on and progression of AD/RD? (2) What are the effects of SARS-CoV-2 variants: ex,nct strains e.g. Wuhan, alpha, delta vs. current strains e.g. omicron and its lineage, and their sequen,al infec,on on AD/RD ini,a,on and progression? (3) What are the effects of prior infec,ons with other highly prevalent viruses e.g. HSV-1 on the ini,a,on and progression of AD/RD by SARS-CoV-2? Successful comple,on of this work will probe the rela,onship between COVID-19 and neurodegenera,on, while yielding deep mechanis,c insights into the role of SARS-CoV-2 in combina,on with HSV-1 in triggering/accelera,ng an AD phenotype and focus a search for therapeu,c targets to counteract AD ini,a,on/accelera,on/progression.", "keywords": [ "2019-nCoV", "Acceleration", "Acids", "Alleles", "Alzheimer's Disease", "Alzheimer's disease model", "Alzheimer's disease pathology", "Alzheimer's disease related dementia", "Amyloid", "Amyloid beta-Protein Precursor", "Apolipoprotein E", "Automobile Driving", "COVID-19", "COVID-19 impact", "Code", "Common Cold", "Complex", "Coronavirus", "Coupled", "Development", "Disease", "Exercise", "Familial disease", "Genes", "Herpesvirus 1", "Histopathology", "Image", "Impairment", "Inflammatory", "Interferons", "Interleukin-1", "Interleukin-6", "Link", "MAPT gene", "Magnetic Resonance Imaging", "Measurement", "Measures", "Memory", "Memory Loss", "Metabolism", "Methodology", "Methods", "Modeling", "National Institute of Neurological Disorders and Stroke", "Neurofibrillary Tangles", "Pathology", "Pathway interactions", "Phenotype", "Pick Disease of the Brain", "Process", "Psyche structure", "Recording of previous events", "Reporting", "Risk", "Risk Factors", "Role", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 variant", "Severity of illness", "Signal Transduction", "Study models", "Tauopathies", "Testing", "Transgenic Mice", "Viral", "Virus", "Work", "apolipoprotein E-4", "brain fog", "cytokine", "disease model", "experience", "human coronavirus", "hyperphosphorylated tau", "in vivo imaging", "insight", "mouse model", "neuropathology", "novel", "post-COVID-19", "presenilin-1", "response", "tau Proteins", "theories", "transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "15818", "attributes": { "award_id": "1U54HD121579-01", "title": "Project 3- Access Study", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2025-09-15", "end_date": "2030-08-31", "award_amount": 204764, "principal_investigator": { "id": 44226, "first_name": "Kimberly Ann", "last_name": "Chapman", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2610, "ror": "", "name": "BAYLOR COLLEGE OF MEDICINE", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "7. ABSTRACT – PROJECT 3 (TELEHEALTH VS VIRTUAL VISITS IN ORGANIC ACIDEMIAS) In a recent survey from the National Organization for Rare Disorders (NORD), nearly 40% of patients/caregivers with rare disorders reported traveling more than 60 miles for medical care. The same survey also found that 70% of respondents would like the option of telehealth for medical appointments and that during the SARS-CoV-2 pandemic, 88% of those offered a video appointment accepted. Of those accepting a video visit, 92% said it was a positive experience. In addition to the access to care issues, the NORD survey also found that 62% of patients with rare diseases were not able to attend work due to their appointments, and that 26% of children missed school regularly for appointments. Consequently, NORD is strongly advocating robust access to telehealth services for patients with rare diseases. Access to care for rare organic acidemias is an even greater challenge. In a recent survey by the Organic Acidemia Association and Propionic Acidemia Foundation, access to care was a top concern for individuals and families. According to the American Board of Medical Genetics and Genomics website, ten US states have no provider certified in either clinical or medical biochemical genetics demonstrating a significant gap in access to local specialists with expertise in organic acidemias. Although telemedicine has been shown to be effective for genetic counseling and genetic patient evaluations, care for individuals with organic acidemias involves more than counseling and diagnosis. Treatment for organic acidemias is complex requiring a combination of low protein diets, medications/supplements, strict adherence to treatment regimens, and the implementation of sick-day protocols in collaboration with the healthcare team. Frequent monitoring of growth, nutrition, and laboratory values and ongoing education are critical to successfully managing organic acidemias. We hypothesize that telehealth is one strategy for increasing access to high-quality care for organic acidemias. To test this hypothesis, we will perform the first large, multi-center study evaluating the efficacy of telehealth for organic acidemias with the following aims: 1) Assess whether virtual clinic visits are equivalent to in-person visits at achieving treatment goals, 2) Compare attendance at clinic visits and knowledge of treatment regimens for those receiving care at virtual and in-person visits, and 3) Assess patient and parent satisfaction and patient-care team relationships with virtual clinic visits compared to in-person visits. Overall, this multi-center, longitudinal study of virtual vs. in-person medical visits will demonstrate whether virtual visits are effective at providing high quality care for individuals with these disorders. As virtual visits may be a strategy for increasing access to clinical trials and meeting enrollment goals in trials for organic acidemias, the results of this study are important for both clinical trial readiness and improving patient access to quality care.", "keywords": [ "Acute", "Adherence", "Advocate", "American", "Appointment", "Area", "Biochemical", "Biochemical Genetics", "COVID-19 pandemic", "Caregivers", "Caring", "Certification", "Child", "Client satisfaction", "Clinic Visits", "Clinical", "Clinical Trials", "Collaborations", "Collection", "Complex", "Counseling", "Diagnosis", "Diet", "Disease", "Education", "Emergency department visit", "Enrollment", "Evaluation", "Event", "Family", "Foundations", "Genetic", "Genetic Counseling", "Genomics", "Goals", "Growth", "Health Services", "Health Services Accessibility", "Hospitalization", "Illness Days", "Improve Access", "Inborn Errors of Metabolism", "Individual", "Knowledge", "Laboratories", "Logistics", "Longitudinal Studies", "Measures", "Medical", "Medical Care Team", "Medical Genetics", "Metabolic", "Monitor", "Multicenter Studies", "Nutrition", "Outcome", "Outcome Assessment", "Outpatients", "Parents", "Participant", "Patient Care Team", "Patients", "Persons", "Pharmaceutical Preparations", "Protein-Restricted Diet", "Protocols documentation", "Provider", "Quality of Care", "Randomized", "Rare Diseases", "Regimen", "Reporting", "Research", "Respondent", "Schools", "Specialist", "Structure", "Surveys", "Telemedicine", "Testing", "Travel", "Treatment Protocols", "US State", "Visit", "Work", "acute care", "care providers", "clinical trial readiness", "dietary", "efficacy evaluation", "experience", "gaps in access", "genetics clinic", "improved", "improved outcome", "ketotic hyperglycinemia", "medical appointment", "meetings", "metropolitan", "patient advocacy group", "satisfaction", "telehealth", "therapeutically effective", "video visit", "virtual", "virtual visit", "web site" ], "approved": true } }, { "type": "Grant", "id": "15882", "attributes": { "award_id": "1K99AI194972-01", "title": "The Role of Tunneling Nanotubes and Mitochondrial programming in HIV-Associated Placental Dysfunction", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44315, "first_name": "UDAY K", "last_name": "SHANKAR", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-09-01", "end_date": "2027-08-31", "award_amount": 156744, "principal_investigator": { "id": 44316, "first_name": "Rafael", "last_name": "Tomoya Michita", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2610, "ror": "", "name": "BAYLOR COLLEGE OF MEDICINE", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT HIV is known to be transmissible from mother to the developing fetus during pregnancy, leading to adverse health outcomes for both. Although HIV is linked to placental pathologies, there is still a large gap in knowledge about the mechanisms underlying HIV-associated pregnancy complications, despite four decades of research in general on HIV topics. The objective of this project is to investigate the role of intercellular conduits composed of F-actin microtubules that connect plasma membranes of neighboring cells enabling cytoplasmic continuing and intercellular transfer of cargo. These conduits are known as tunneling nanotubes (TNTs). Recent investigations by the PI and others have demonstrated that other viruses such as Zika and SARS-CoV-2 induce the formation of TNTs in placental trophoblast cells, and there is evidence they serve as a means of mitochondrial transfer and possibly viral transfer that promotes infectious spread. There is evidence that HIV induces TNT formation in neurons, but it is not known whether the virus has this effect on placental cells. Building on prior studies and ongoing work by the PI, the central hypothesis of this project is that HIV uses TNTs to spread infection in trophoblasts, and that TNTs mediate placental dysfunction by transferring damaged mitochondria and adversely reprogramming trophoblast metabolism. This metabolic reprogramming may contribute to placental dysfunction and adverse pregnancy outcomes. Aim 1 of this project will elucidate the molecular mechanisms of TNT formation between HIV-infected immune cells and trophoblasts. Aim 2 will determine the impact of HIV on mitochondrial dynamics and transfer and resulting trophoblast function. These two aims will be pursued during the final postdoctoral training period of the K99 phase. Aim 3 seeks to identify how HIV-exposed mitochondria reprogram trophoblast biology, impairing placental function and affecting fetal development in vivo. This third aim will be pursued during the R00 phase of the project. Successful completion of these aims will provide new insights into the mechanisms underlying HIV infection, identifying potential therapeutic targets to mitigate vertical transmission and placental pathologies caused by HIV and other viruses. During the mentored phase, the PI will gain expertise in primary cell culture, metabolomics, trophoblast organoids, and mitochondrial epigenetics to examine how HIV infects the placenta and disrupts cellular metabolism—establishing a foundation for the R00 phase. With guidance from the advisory team, this training and research will contribute to the identification of therapeutic strategies to improve outcomes for infants and individuals with HIV, while positioning the investigator to establish an independent, competitive R01-funded laboratory at the intersection of HIV, TNTs, placental biology, and mitochondria.", "keywords": [ "2019-nCoV", "Actins", "Advisory Committees", "Affect", "Affinity Chromatography", "Anti-viral Response", "Automobile Driving", "Biology", "Bypass", "Cell Physiology", "Cell Separation", "Cell Survival", "Cell fusion", "Cell membrane", "Cells", "Chronic", "Cloning", "Coculture Techniques", "Confocal Microscopy", "Coupled", "Cytoplasm", "Cytoskeleton", "DNA", "Data", "Deoxyadenosines", "Development", "Disproportionately impacts women", "Epigenetic Process", "F-Actin", "Fetal Development", "Fetus", "Flow Cytometry", "Foundations", "Functional disorder", "Funding", "Genes", "Genetic Transcription", "HIV", "HIV Infections", "HIV-1", "Health", "Image Cytometry", "Immune", "Immune Evasion", "Immune response", "Immunoprecipitation", "Impairment", "In Vitro", "Individual", "Infection", "Inflammation", "Investigation", "Knowledge", "Label", "Laboratories", "Link", "Mass Spectrum Analysis", "Measures", "Mediating", "Mentors", "Metabolic", "Metabolic Pathway", "Metabolic dysfunction", "Metabolism", "Microtubules", "Mitochondria", "Mitochondrial DNA", "Modeling", "Modification", "Molecular", "Mothers", "Mus", "Mutation", "Neurons", "Organoids", "Outcome", "Oxidative Phosphorylation", "Pathology", "Pathway interactions", "Patients", "Perinatal Infection", "Phase", "Placenta", "Placental Biology", "Positioning Attribute", "Pregnancy", "Pregnancy Complications", "Pregnant Women", "Primary Cell Cultures", "Process", "Proteins", "Quantitative Reverse Transcriptase PCR", "Reactive Oxygen Species", "Recombinants", "Regulation", "Research", "Research Personnel", "Risk", "Role", "Site-Directed Mutagenesis", "Study models", "System", "T-Lymphocyte", "Techniques", "Tertiary Protein Structure", "Testing", "Therapeutic", "Training", "Validation", "Vertical Transmission", "Viral", "Virion", "Virus", "Virus Diseases", "Visualization", "Western Blotting", "Work", "ZIKA", "Zika Virus", "adverse pregnancy outcome", "antiretroviral therapy", "experimental study", "fetal", "global health", "heteroplasmy", "improved outcome", "in vivo", "infant outcome", "insight", "knock-down", "live cell imaging", "metabolomics", "mitochondrial dysfunction", "mouse model", "mutant", "placental trophoblasts", "post-doctoral training", "pregnant", "programs", "protein protein interaction", "reproductive age", "single molecule real time sequencing", "single-cell RNA sequencing", "stem cells", "therapeutic target", "transmission process", "tropho" ], "approved": true } }, { "type": "Grant", "id": "15740", "attributes": { "award_id": "1R43TR005424-01", "title": "A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32559, "first_name": "PJ", "last_name": "BROOKS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2026-07-31", "award_amount": 349746, "principal_investigator": { "id": 32603, "first_name": "Hari", "last_name": "Bhaskaran", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2611, "ror": "", "name": "CISTERNA BIOLOGICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "With the success of mRNA-based Covid vaccines, there is immense interest in leveraging mRNA technology to develop therapeutics for previously untreatable diseases. However, therapeutic applications, such as protein replacement therapy, cardiovascular regeneration, and cancer immunotherapy, require mRNA of exceptional purity to ensure safety and efficacy. Current mRNA production methods often yield mRNA with impurities, such as double-stranded RNA (dsRNA), long RNA (LRNA), and short truncated (stRNA), which can provoke immune responses and compromise therapeutic outcomes. Cisterna has developed an innovative platform capable of synthesizing high-quality, purified mRNA, devoid of product-related contaminants, making it ideal for therapeutic use while ensuring consistency and reproducibility across batches. In this Phase I SBIR, our goal is to demonstrate the efficacy of our technology in eliminating dsRNA, LRNA, and stRNA compared to conventional methods. We will employ sensitive fluorescence-based methods and assays to quantify and eliminate these impurities, enabling the production of highly pure therapeutic mRNA. Furthermore, we will validate our technology by assessing its impact on immunogenic response and protein expression in mice, aiming for minimal to no immune activation while maintaining or enhancing therapeutic efficacy. Successful completion of this project will provide a validated production platform for contaminant-free mRNA synthesis, paving the way for Phase II studies focused on target identification, construct design, and scale-up manufacturing. The mRNA therapeutics market is poised for significant growth, with biotech and pharmaceutical companies actively developing mRNA-based therapeutics. We aim to leverage potential partnerships to position ourselves as a key player in this dynamic field.", "keywords": [ "Address", "Advanced Development", "Affect", "Antibodies", "Biological Assay", "Biological Products", "Biotechnology", "COVID-19 vaccine", "Cardiovascular system", "Catalytic RNA", "Cellulose", "Consumption", "Detection", "Development", "Disease", "Dose", "Dot Immunoblotting", "Double-Stranded RNA", "Engineering", "Ensure", "Enzymes", "Event", "Excision", "Fluorescence", "Gel", "Goals", "Growth", "Hela Cells", "High Pressure Liquid Chromatography", "Immune", "Immune response", "Innate Immune Response", "Legal patent", "Length", "Longevity", "Luciferases", "Malignant Neoplasms", "Marketing", "Measures", "Messenger RNA", "Metabolic", "Methods", "Modeling", "Mus", "Natural regeneration", "Pharmacologic Substance", "Phase", "Positioning Attribute", "Process", "Production", "RNA", "Rare Diseases", "Recovery", "Reference Standards", "Regimen", "Reproducibility", "Safety", "Sepharose", "Small Business Innovation Research Grant", "Technology", "Technology Assessment", "Testing", "Therapeutic", "Therapeutic Uses", "Time", "Treatment Efficacy", "Validation", "Variant", "Work", "cancer immunotherapy", "commercial application", "cost", "cytokine", "design", "design and construction", "detection limit", "dosage", "drug development", "effective therapy", "enzyme replacement therapy", "high standard", "immune activation", "immunogenic", "immunogenicity", "in vivo", "innovation", "interest", "manufacturing scale-up", "mouse model", "multiplex assay", "novel strategies", "oligo (dT)", "phase 2 study", "prophylactic", "protein expression", "research and development", "response", "success", "therapy development", "therapy outcome", "tool", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "15741", "attributes": { "award_id": "1R35GM160071-01", "title": "Viral Biosensors of Host Post-Translational Modifications", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22244, "first_name": "MICHAEL", "last_name": "SAKALIAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 420984, "principal_investigator": { "id": 26190, "first_name": "Mehdi", "last_name": "Bouhaddou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2612, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Viruses and their hosts are engaged in a constant, dynamic struggle as part of an ongoing evolutionary arms race. It is well established that viruses continually evolve new offensive strategies, like the production of proteins that disrupt host defenses, while hosts develop countermeasures to detect and neutralize viruses. However, a key question that remains is: how do viruses perceive and respond to host cues in real-time? This ability to sense and adapt to the intracellular environment, akin to real-time \"decision-making,\" which helps them decide when to replicate, assemble, or escape, plays a crucial role in their fitness and ability to spread. To understand how viruses sense and respond to their environment, we will study host-derived post-translational modifications (PTMs) of viral proteins. The overarching hypothesis of this proposal is that viral proteins have evolved as substrates for host enzyme-derived PTMs to equip them with molecular sensors to coordinate viral life cycle transitions. Furthermore, we will study how PTMs enable multifunctionality in viral proteins by creating distinct proteoforms. By understanding the molecular mechanisms of viral biosensors, we expect to pinpoint critical viral dependencies, revealing promising targets for antiviral intervention. PTMs, imposed by the host cell, can dramatically alter the functions of viral proteins, influencing their behavior and ultimately the fate of the virus. Our preliminary mass spectrometry phosphoproteomics analysis of alphavirus infection revealed phosphorylation sites at the capsid-glycoprotein interface, likely regulated by plasma membrane-localized kinases, suggesting a functional switch in glycoproteins at the membrane. We similarly identified phosphorylation sites on herpesvirus latency proteins, which we believe may play a role in allowing the viral genome to replicate alongside the host genome during latency. Lastly, we discovered phosphorylation of a SARS-CoV-2 accessory protein by innate immune kinases, suggesting a feedback mechanism that may modify viral protein function in response to immune activation. Our data have led us to three specific areas of inquiry, each forming a distinct research project being conducted by PhD students, a project scientist, and undergraduate trainees: (1) How do viruses navigate through distinct host subcellular locations during their life cycle? (2) How do viruses coordinate their life cycle with the host cell cycle? (3) How do viruses sense, respond to, and exploit the host innate immune system? The projects and questions outlined in this proposal will serve as the foundation for the primary research in my laboratory over the next five years. Our questions seek to establish a new research area centered on the biochemical mechanisms through which viruses act as biosensors of the host signaling environment, how these biosensors adjust their functionality in response to PTMs, and how targeting these sensors may result in innovative antiviral therapies.", "keywords": [ "2019-nCoV", "Alphavirus Infections", "Anti-viral Therapy", "Area", "Behavior", "Biochemical", "Biosensor", "Capsid", "Cell Cycle", "Cell membrane", "Cells", "Cues", "Data", "Decision Making", "Dependence", "Development", "Disease", "Environment", "Enzymes", "Feedback", "Foundations", "Genome", "Glycoproteins", "Herpesviridae", "Host Defense", "Immune", "Innate Immune System", "Intervention", "Knowledge", "Laboratories", "Life Cycle Stages", "Location", "Mass Spectrum Analysis", "Membrane", "Mission", "Molecular", "Phosphorylation", "Phosphorylation Site", "Phosphotransferases", "Play", "Post-Translational Protein Processing", "Production", "Proteins", "Public Health", "Research", "Research Project Grants", "Role", "Scientist", "Signal Transduction", "Time", "United States National Institutes of Health", "Viral", "Viral Genome", "Viral Physiology", "Viral Proteins", "Virus", "Virus Diseases", "arms race", "doctoral student", "fitness", "immune activation", "innovation", "insight", "novel therapeutic intervention", "phosphoproteomics", "protein function", "response", "sensor", "undergraduate student" ], "approved": true } }, { "type": "Grant", "id": "15742", "attributes": { "award_id": "1R21AI188400-01A1", "title": "Uncovering mechanisms that underpin bat virus virulence", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32795, "first_name": "EUN-CHUNG", "last_name": "PARK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-04", "end_date": "2027-07-31", "award_amount": 455692, "principal_investigator": { "id": 26531, "first_name": "Cara", "last_name": "Brook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2613, "ror": "", "name": "UNIVERSITY OF CALIFORNIA BERKELEY", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Bats are reservoir hosts for zoonoses that cause the highest case fatality rates documented in humans, including rabies and related lyssaviruses, Hendra and Nipah henipaviruses, Ebola and Marburg filoviruses, and SARS and MERS coronaviruses. Bats exhibit limited disease upon infection with these viruses that cause extreme pathology in other mammals, likely due to robust and rapid innate and cell-mediated immune defenses, coupled with hyper-efficient mechanisms of DNA damage repair and dampened inflammatory pathways. Recent theoretical work in our lab demonstrates how these unique features of bat immunology and physiology—chiefly, constitutive antiviral immunity and resilience to inflammation that confers tolerance to immunopathology—should select for the evolution of high virus growth rates that, while avirulent to bats, are likely to cause pathology following spillover to non-bat, including human, hosts. Here, we seek to explicitly test the predictions of our theoretical model by carrying out experimental evolution of vesicular stomatitis virus (VSV) in bat cell cultures that span a range of both (Aim 1) constitutive antiviral and (Aim 2) inflammation tolerant phenotypes. Under Aim 1, we examine variation in VSV growth rate evolution and the rate of molecular evolution following serial passage of virus across a suite of Pteropus alecto bat cell lines that exhibit both intact (wildtype) and deficient (CRISPR knock-outs) antiviral immune functions. Under Aim 2, we leverage our lab’s unique system of primary bat fibroblast cell lines derived from related species spanning a range of longevities to evaluate whether cells derived from longer-lived species that demonstrate resilience to aging-related stressors also exhibit heightened tolerance of virus infection. We then compare VSV evolution following serial passage across cell lines that demonstrate variable resilience to aging-related stressors in vitro. We hypothesize that antiinflammatory properties in bat cells which confer resilience to aging stressors may also facilitate virus tolerance by limiting immunopathology and—by extension—drive the evolution of high growth rate viruses likely to generate pathology in non-bat hosts. Ultimately, we offer an explicit empirical test of the hypothesized mechanisms underpinning the extreme virulence of bat virus zoonoses.", "keywords": [ "Acceleration", "Aging", "Anti-Inflammatory Agents", "Anti-viral Response", "Automobile Driving", "Birds", "Body Size", "Case Fatality Rates", "Cell Culture Techniques", "Cell Line", "Cells", "Chiroptera", "Clustered Regularly Interspaced Short Palindromic Repeats", "Coupled", "DNA Repair", "Data", "Disease", "Ebola", "Evolution", "Exhibits", "Fibroblasts", "Filovirus", "Genes", "Genome", "Genus Pteropus", "Growth", "Harvest", "Hendra Virus", "Human", "IFNAR2 gene", "IRF1 gene", "IRF3 gene", "Immune", "Immune response", "Immunity", "Immunologics", "Immunology", "In Vitro", "Indiana", "Infection", "Inflammation", "Inflammatory", "Interferons", "Knock-out", "Link", "Literature", "Locomotion", "Longevity", "Lyssavirus", "Mammals", "Marburgvirus", "Mediating", "Metabolic", "Metabolic stress", "Middle East Respiratory Syndrome Coronavirus", "Molecular", "Molecular Evolution", "Nipah Virus", "Paper", "Pathology", "Pathway interactions", "Phenotype", "Physiological", "Physiology", "Plaque Assay", "Process", "Property", "Public Health", "RNA", "Rabies", "Regulator Genes", "Research", "Residual state", "Resistance", "SARS coronavirus", "Secondary to", "Serial Passage", "Serotyping", "Signal Transduction", "System", "Testing", "Theoretical model", "Variant", "Vesicular stomatitis Indiana virus", "Viral", "Viral Load result", "Virulence", "Virulent", "Virus", "Virus Diseases", "Work", "Zoonoses", "aging related", "anti aging", "antiviral immunity", "burden of illness", "cellular resilience", "comparative", "cost", "experience", "experimental study", "extend lifespan", "immune function", "immunopathology", "life span", "oxidative damage", "predictive modeling", "rapid growth", "resilience", "resilience in aging", "response", "stressor", "theories", "trait", "transcriptome sequencing", "transcriptomics", "transmission process", "viral resistance" ], "approved": true } }, { "type": "Grant", "id": "15743", "attributes": { "award_id": "1R34HL173375-01A1", "title": "Democratizing Access to Cleaner Residential Air (DACRA)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32796, "first_name": "MICHELLE M", "last_name": "FREEMER", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-15", "end_date": "2028-07-31", "award_amount": 293395, "principal_investigator": { "id": 32797, "first_name": "Doug", "last_name": "Brugge", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2614, "ror": "", "name": "UNIVERSITY OF CONNECTICUT SCH OF MED/DNT", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Particulate air pollution (PM2.5) is the 4th leading cause of morbidity and mortality. Attention from leading health organizations has recently turned to interventions to reduce exposure and prevent adverse health outcomes. As evidence has begun to mount for the efficacy of these machines, and will likely grow further in the coming years, it has, however, become apparent that for most people, including low-income populations in the US, cannot afford effective commercially available units. Low-cost commercial air purifiers are of low efficacy and often introduce new pollutants into the air. To our knowledge, there are no published intervention studies of Corsi-Rosenthal Boxes (C-R Boxes), the devices we propose to use in this study. We have a study team that is ideally suited for the proposed research. Ms. Creed has extensive experience building and deploying the C-R Boxes which became popular during the Covid pandemic. Dr. Brugge has three published RCTs of high-quality commercial air purifiers and another, full trial, nearing completion. Thus, he has knowledge and experience which qualifies him to lead this proposed study. Drs. Levy Zamora has extensive air monitoring expertise, will direct measurement of indoor and outdoor air pollution concentrations at each home. Dr. Eliasziw is a biostatistician with extensive experience analyzing randomized trials. We have three aims: 1)Conduct focus groups/interviews and BP measurements with participants who meet study inclusion criteria to refine our protocol; 2) Conduct a randomized crossover pilot trial with 65 participants to calculate preliminary effect size estimates to inform a larger crossover efficacy trial; and 3) Determine the feasibility of conducting a larger crossover efficacy multisite trial in the US. We will conduct our randomized cross over trial in three settings with low, medium, and high air pollution. Our low and medium air pollution locations will be in Hartford CT and our high pollution setting will be in Boston Chinatown, where we can reliably expect high pollution levels. Participants (N=65) will have dried blood spots collected and blood pressure measured at the start and end of each 4-week intervention session. Our randomized cross over design controls for time invariant confounding. Interviews and standardized questionnaires with study participants will provide feedback that will inform the decision as to whether to proceed with a full trial. We seek to meet targets for 80% recruitment and retention as well as 80% satisfaction as benchmarks for moving to a full trial. The findings for health end points will provide preliminary data to justify the potential future R01 proposal for a fully powered clinical trial. An expert elicitation process conducted with the research team in the final year will make the final decision about a future, full trial. The significance of this work is that showing efficacy of C-R Boxes for reducing exposure would lead to their widespread use and contribute to improving public health", "keywords": [ "Africa", "Air", "Air Movements", "Air Pollutants", "Air Pollution", "Allergens", "American Heart Association", "Asia", "Attention", "Benchmarking", "Biological Markers", "Blood", "Blood Glucose", "Blood Pressure", "Boston", "COVID-19 pandemic", "Cardiopulmonary", "Cardiovascular Diseases", "Cardiovascular system", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Childhood Asthma", "Clinical Trials", "Consensus", "Country", "Cross-Over Trials", "Crossover Design", "Data", "Developed Countries", "Devices", "Diet", "Dryness", "Educational workshop", "Exposure to", "Fasting", "Feedback", "Filtration", "Focus Groups", "Future", "Goals", "Health", "Health Benefit", "Home", "Hour", "Household", "Income", "Indoor Air Pollution", "Inflammation", "Interleukin-6", "Intervention", "Intervention Studies", "Interview", "Knowledge", "Lead", "Link", "Location", "Low Income Population", "Measurement", "Measures", "Meta-Analysis", "Morbidity - disease rate", "Outcome", "Participant", "Particulate", "Particulate Matter", "Persons", "Pollution", "Power Sources", "Predisposition", "Process", "Protocols documentation", "Public Health", "Publishing", "Qualifying", "Questionnaires", "Randomized", "Research", "Risk", "Sampling", "Spottings", "Standardization", "Time", "Tobacco", "Translating", "United States Environmental Protection Agency", "United States National Institutes of Health", "Vulnerable Populations", "Whole Blood", "Work", "acceptability and feasibility", "air filter", "air monitoring", "ambient air pollution", "cost", "efficacy trial", "epidemiology study", "experience", "feasibility testing", "feasibility trial", "fine particles", "health assessment", "health organization", "health related quality of life", "high risk population", "improved", "inclusion criteria", "indoor concentrations", "inflammatory marker", "innovation", "meter", "mortality", "multi-site trial", "noise perception", "particle", "peripheral blood", "pilot trial", "pollutant", "portability", "prevent", "randomized trial", "randomized clinical trials", "recruit", "respiratory", "satisfaction", "systematic review", "systemic inflammatory response" ], "approved": true } }, { "type": "Grant", "id": "15744", "attributes": { "award_id": "1U19AI189183-01", "title": "Accelerator for the rapid development of countermeasures targeting drug resistant fungal pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32798, "first_name": "PING", "last_name": "CHEN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-06-30", "award_amount": 6977446, "principal_investigator": { "id": 8841, "first_name": "Arturo", "last_name": "Casadevall", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23143, "first_name": "David S", "last_name": "Perlin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1487, "ror": "https://ror.org/008zj0x80", "name": "Hackensack University Medical Center", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Invasive fungal infections pose a significant medical challenge, particularly for individuals with compromised immune systems or other conditions due to HIV, cancer, organ transplantation, diabetes, chronic respiratory ailments, tuberculosis, COVID-19, and influenza. Prompt diagnosis and effective antifungal treatment are crucial for positive clinical outcomes. Current antifungal drugs are limited in number and efficacy, and their effectiveness has been compromised by the emergence of drug-resistant strains, notably Candida auris, Candida glabrata, and Aspergillus fumigatus. To combat this growing problem, there is an urgent need to develop new drugs capable of effectively treating invasive infections caused by drug-resistant fungal pathogens. Additionally, actionable point-of-care diagnostics for Candida bloodstream infections are essential for initiating timely and appropriate therapy, ultimately reducing overall mortality rates. While efforts from the biopharmaceutical industry have led to some expansion in the antifungal pipeline, more potent and targeted drugs are urgently required. In response to these pressing challenges, a Center of Excellence in Translational Research (CETR) focused on rapid drug and diagnostic development will be established. This Center harnesses expertise of leading academic and industry professionals, many of whom have a track record of successfully bringing FDA-approved products to market. The Projects selected encompass a wide range of new and established pharmacological drug targets, as well as a state-of-the-art diagnostic platform. Among the projects underway, collaborations with biopharmaceutical partners Prokaryotics and Scynexis are focused on the development of advanced small molecules targeting key enzymes involved in cell wall biogenesis. Additionally, efforts are underway to develop an antibody-based immunotherapy to combat drug-resistant infections. Finally, a Project dedicated to creating a novel point-of-care diagnostic capable of rapidly detecting Candida bloodstream infections in partnership with Cepheid Diagnostics on the GeneXpert platform, holds promise for revolutionizing the diagnosis and management of fungal infections. An integrated network of science cores staffed by experienced directors, facilitate efficient compound optimization and progression through clear ‘go, no-go’ metrics. While all programs prioritize high-threat drug-resistant Candida species, some drug candidates may also demonstrate efficacy against azole-resistant Aspergillus fumigatus. In summary, this CETR-based drug and diagnostic development accelerator represents a concerted effort to address the pressing need for novel treatments and diagnostics for invasive fungal infections. By leveraging the expertise of industry and world class translational academic partners, this initiative aims to rapidly advance innovative solutions to combat antifungal drug resistance and improve clinical outcomes for patients affected by these challenging fungal infections. The anticipated outcome of our successful efforts will be to create two IND-ready small molecule drug candidates, a lead optimized novel immunotherapy, and a 510(k) ready point-of-care diagnostic for bloodstream infections.", "keywords": [ "Academia", "Acceleration", "Address", "Advanced Development", "Affect", "Animal Model", "Antibodies", "Aspergillus fumigatus", "Azole resistance", "Biogenesis", "Biological Products", "Blood", "COVID-19", "Candida", "Candida auris", "Candida glabrata", "Cell Wall", "Chronic", "Clinical", "Collaborations", "Death Rate", "Dedications", "Detection", "Development", "Diabetes Mellitus", "Diagnosis", "Diagnostic", "Disease", "Drug Targeting", "Drug resistance", "Effectiveness", "Ensure", "Enzymes", "FDA approved", "Fungal Drug Resistance", "GPI Membrane Anchors", "Goals", "HIV", "Immune system", "Immunocompromised Host", "Immunotherapy", "Individual", "Industry", "Infection", "Influenza", "Investigational Drugs", "Knowledge", "Lead", "Life", "Malignant Neoplasms", "Marketing", "Medical", "Microbiology", "Mission", "Mycoses", "Organ Transplantation", "Outcome", "Patient-Focused Outcomes", "Pharmaceutical Chemistry", "Pharmaceutical Preparations", "Pharmacology", "Pharmacotherapy", "Process", "Productivity", "Public Health", "Rapid diagnostics", "Records", "Resistance", "Resistant candida", "Resources", "Respiration Disorders", "Science", "Standardization", "The science of Mycology", "Therapeutic", "Time", "Translational Research", "Transplantation", "Tuberculosis", "anti-fungal agents", "biopharmaceutical industry", "bloodstream infection", "combat", "diagnostic development", "diagnostic platform", "diagnostic tool", "diagnostic value", "drug candidate", "drug development", "experience", "formulation optimization", "glucan synthase", "improved", "in vivo", "in vivo Model", "innovation", "lead optimization", "mannoproteins", "mortality", "novel", "novel therapeutics", "pathogen", "pathogenic fungus", "pharmacologic", "point of care", "point-of-care diagnostics", "preclinical development", "prevent", "programs", "rapid detection", "resistant Aspergillus", "resistant strain", "respiratory", "response", "small molecule" ], "approved": true } }, { "type": "Grant", "id": "15756", "attributes": { "award_id": "1R01AI190195-01", "title": "The Impact of Systemic Immunosuppression on RSV Antibody Generation and Effector Functions After Vaccination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21312, "first_name": "SONNIE", "last_name": "KIM", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 775187, "principal_investigator": { "id": 32819, "first_name": "Andrew Hoover", "last_name": "Karaba", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Immunosuppressed persons (ISPs) have a nearly 40% risk of hospitalization if infected with respiratory syncytial virus (RSV). Recently, novel RSV vaccines based on the prefusion F protein of the virus were found to be effective at reducing RSV disease, but these were not tested in high-risk ISPs. Owing to immunosuppression, ISPs often develop attenuated antibody responses to vaccines and require either additional doses or different formulations to achieve protective levels of antibodies. Antibodies against prefusion F are associated with protection from RSV disease and thought to be central to the protection afforded by RSV vaccines. Our preliminary data indicate that, among ISPs, the antibody response to RSV vaccines is heterogeneous, with many ISPs demonstrating minimal or no response. However, the nature of this decreased response (i.e. unrecognized antibody epitopes and impact on neutralizing and non-neutralizing functions) remains unknown. Furthermore, the influence of specific immunosuppressive medications and the type of vaccine received (adjuvanted vs. unadjuvanted) is undetermined. To protect this high-risk group from this common and often devastating infection, a comprehensive understanding of the antibody response to these vaccines by ISPs is necessary and will improve vaccine recommendations, design, and medication management. The proposed research will address these uncertainties by systematically studying the antibody response to novel RSV vaccines in a national observational cohort of ISPs, comparing the responses to those of healthy participants (HPs). This national cohort of highly engaged ISPs was critical in our previous successful efforts to define the effects of immunosuppression on SARS-CoV-2 vaccination, and we will leverage this opportunity to discern the impact of immunosuppression on antibody responses to RSV vaccines. We will accomplish this by quantifying the prefusion F and neutralizing antibody response longitudinally in these groups and determining the impact of vaccine type (adjuvanted vs. unadjuvanted), type of immunosuppressive medication, and demographic factors (Aim 1). Additionally, we will study the entire viral antibody epitope landscape before and after vaccination using innovative DNA barcoded-protein technology to identify key gaps in epitope recognition, measure the impact of pre-existing immunity on vaccine responses, and correlate specific epitope responses with antibody function (Aim 2). Finally, the researchers will measure the effect of immunosuppression and vaccine adjuvant on antibody subtype, subclass, and non-neutralizing functions using a systems serology approach (Aim 3). The investigators’ established productive collaborative relationships, extensive experience studying antibody responses in high-risk and/or immunosuppressed populations, and this cohort of ISPs provide the ideal circumstances to provide critical knowledge that promises to be directly applicable to improving RSV vaccine responses in this high-risk group and inform future vaccine design for immunosuppressed persons.", "keywords": [ "Adjuvant", "Antibodies", "Antibody Formation", "Antibody Response", "Attenuated", "Autoimmune Diseases", "Bar Codes", "COVID-19 vaccination", "COVID-19 vaccine", "Cells", "Clinical", "Clinical Trials", "Complement Activation", "Complex", "DNA", "Data", "Demographic Factors", "Disease", "Dose", "Enzyme-Linked Immunosorbent Assay", "Epitopes", "Formulation", "Future", "Generations", "Goals", "Hospitalization", "Immune response", "Immune signaling", "Immunity", "Immunocompromised Host", "Immunoglobulin A", "Immunoglobulin G", "Immunoglobulin M", "Immunologics", "Immunosuppression", "Individual", "Infection", "Innate Immune System", "Knowledge", "Measures", "Medication Management", "Modeling", "Molecular", "Nature", "Older Population", "Participant", "Peptides", "Persons", "Pharmaceutical Preparations", "Play", "Population", "Process", "Productivity", "Proteins", "Recommendation", "Regimen", "Research", "Research Personnel", "Respiratory Syncytial Virus Infections", "Respiratory Syncytial Virus Vaccines", "Respiratory syncytial virus", "Risk", "Role", "Serology", "Solid", "System", "Technology", "Testing", "Toxic effect", "Uncertainty", "Vaccination", "Vaccine Adjuvant", "Vaccine Design", "Vaccines", "Viral", "Viral Antibodies", "Viral Proteins", "Virus", "Virus Diseases", "antibody-dependent cell cytotoxicity", "attenuation", "cohort", "design", "disorder prevention", "experience", "high risk", "high risk population", "immune activation", "immunogenicity", "immunosuppressed", "improved", "in vitro Model", "indexing", "innovation", "machine learning model", "neutralizing antibody", "novel", "organ transplant recipient", "pathogen", "pharmacologic", "response", "self assembly", "vaccine access", "vaccine immunogenicity", "vaccine response" ], "approved": true } }, { "type": "Grant", "id": "15762", "attributes": { "award_id": "1K08AI193077-01", "title": "Impact of Spatial and Social Determinants on Invasive Fungal Infection Risk", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32829, "first_name": "DONA", "last_name": "LOVE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 197640, "principal_investigator": { "id": 32830, "first_name": "Lucy", "last_name": "Li", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": ": Invasive fungal infections (IFIs) are a growing public health challenge, leading to over 1.5 million deaths each year worldwide. Contextual factors are believed to be critical components of IFI risk as evidenced by historical fungal outbreaks associated with specific geographic distributions and ecological disruptions. Certain communities are thought to be particularly vulnerable with greater exposure to high-risk contextual factors, leading to higher rates of and worse outcomes from IFIs. In addition, socioeconomic status may impact IFI outcomes, due to delays in diagnosis, access to care, and quality of care. However, prior studies of IFI epidemiology have focused primarily on host factors without adequately considering the uneven distribution of hazards and their spatiotemporal trends related to socioeconomic factors. The objective of this proposal is to assess the impact of social determinants on IFI risk by leveraging a national data source, the National COVID Cohort Collaborative, and a more granular hospital system electronic-health medical records data source. In Aim 1, we will determine neighborhood-level contextual and socioeconomic predictors of IFIs. In Aim 2, we will examine the association between individual socioeconomic status factors and clinical outcomes of IFIs. This work will advance our understanding of the spatial and social determinants of IFI risk and outcomes as well as provide a robust training platform for the award recipient, Dr. Lucy Li. Through both research and career development training, Dr. Li will acquire essential skills in large data analysis, including advanced methods in spatial science and social factors research, time series analyses, and risk prediction modeling. Dr. Li will then be well positioned to be an independent clinical investigator focused on IFIs in at-risk populations with an expertise in integrating spatial and social factors data into population health analyses.", "keywords": [ "Address", "Affect", "Air", "Allergic", "American", "Area", "Asthma", "Award", "COVID-19", "Caring", "Censuses", "Cessation of life", "Clinical", "Clinical Investigator", "Clinical Research", "Communities", "Community Surveys", "Computerized Medical Record", "Data", "Data Analyses", "Data Commons", "Data Sources", "Databases", "Diagnosis", "Dimensions", "Disease", "Disease Outbreaks", "Education", "Electronic Health Record", "Employment Status", "Epidemiology", "Equation", "Ethnic Origin", "Exposure to", "Geographic Distribution", "Geographic Locations", "Health Services Accessibility", "Health system", "Hospitalization", "Hospitals", "Housing", "Immunocompetent", "Immunocompromised Host", "Incidence", "Income", "Individual", "Infection", "Insurance Coverage", "Integration Host Factors", "International Classification of Disease Codes", "Intervention", "Length of Stay", "Logistic Regressions", "Longitudinal trends", "Measures", "Mentors", "Methods", "Molds", "Mycoses", "Neighborhoods", "Organ", "Outcome", "Outcome Assessment", "Patients", "Pattern", "Persons", "Play", "Population", "Populations at Risk", "Positioning Attribute", "Public Health", "Quality of Care", "Race", "Research", "Resolution", "Risk", "Risk Factors", "Science", "Seasons", "Shapes", "Site", "Socioeconomic Factors", "Socioeconomic Status", "Source", "System", "Time Series Analysis", "Training", "United States", "Weather", "Work", "Yeasts", "adjudication", "career", "career development", "clinical care", "clinical risk", "cohort", "contextual factors", "design", "electronic medical record system", "fungus", "hazard", "high risk", "improved", "indexing", "infection risk", "low socioeconomic status", "mortality", "multilevel analysis", "patient screening", "population health", "primary outcome", "research and development", "risk prediction", "risk prediction model", "secondary outcome", "skills", "social determinants", "social factors", "social vulnerability", "socioeconomics", "spatial epidemiology", "spatial integration", "spatial relationship", "spatiotemporal", "statistics", "time use", "trend" ], "approved": true } } ], "meta": { "pagination": { "page": 1405, "pages": 1424, "count": 14236 } } }